Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Puma Biotechnology (PBYI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,656,967
  • Shares Outstanding, K 38,030
  • Annual Sales, $ 27,690 K
  • Annual Income, $ -291,960 K
  • 36-Month Beta -0.23
  • Price/Sales 63.23
  • Price/Cash Flow N/A
  • Price/Book 43.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -1.07
  • Number of Estimates 2
  • High Estimate -1.03
  • Low Estimate -1.11
  • Prior Year -2.07
  • Growth Rate Est. (year over year) +48.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.25 +4.80%
on 10/15/18
48.80 -13.57%
on 09/20/18
-5.62 (-11.76%)
since 09/19/18
3-Month
40.25 +4.80%
on 10/15/18
54.20 -22.18%
on 08/10/18
-10.27 (-19.58%)
since 07/19/18
52-Week
40.25 +4.80%
on 10/15/18
136.90 -69.19%
on 11/08/17
-79.42 (-65.31%)
since 10/19/17

Most Recent Stories

More News
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT onThursday, November 1, 2018 following release of its third...

PBYI : 42.18 (-3.19%)
Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance

Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.

PBYI : 42.18 (-3.19%)
LLY : 111.92 (-1.23%)
RHHBY : 30.5950 (+2.55%)
GSK : 40.87 (+3.18%)
Shares of Fibrogen Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (FGEN , PBYI , PTLA , CLVS , MNTA )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

PBYI : 42.18 (-3.19%)
FGEN : 52.90 (-3.17%)
PTLA : 21.91 (-2.45%)
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arsanis, Inc. (NASDAQ:ASNS),...

CDXS : 15.32 (-3.16%)
PBYI : 42.18 (-3.19%)
ASNS : 1.50 (+1.35%)
DVAX : 10.89 (-4.22%)
OPK : 3.59 (-2.18%)
ADAP : 10.76 (-1.10%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 9, 2018, the Compensation Committee of Puma's Board of Directors approved the grant of inducement...

PBYI : 42.18 (-3.19%)
CANbridge Pharmaceutical Submits New Drug Application for NERLYNX(R) (neratinib) in China

CANbridge Pharmaceutical Inc., a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that it has filed a New Drug Application (NDA) to China's...

PBYI : 42.18 (-3.19%)
Puma Biotechnology to Present at Cantor Global Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview...

PBYI : 42.18 (-3.19%)
PBYI November 16th Options Begin Trading

Investors in Puma Biotechnology Inc saw new options become available today, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PBYI options...

PBYI : 42.18 (-3.19%)
Watch for Puma Biotechnolo to Potentially Rebound After Falling 5.43% Yesterday

Puma Biotechnolo (NASDAQ:PBYI) traded in a range yesterday that spanned from a low of $44.20 to a high of $46.75. Yesterday, the shares fell 5.4%, which took the trading range below the 3-day low of...

PBYI : 42.18 (-3.19%)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 5, 2018 the Compensation Committee of Puma's Board of Directors approved the grant of inducement...

PBYI : 42.18 (-3.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade PBYI with:

Business Summary

Puma Biotechnology, Inc. is a biopharmaceutical company focused on the acquisition, in-licensing, development and commercialization of novel therapeutics for the treatment of cancer. Its products under development include PB272 (oral neratinib) for the treatment of patients with human epidermal growth...

See More

Key Turning Points

2nd Resistance Point 46.92
1st Resistance Point 44.55
Last Price 42.18
1st Support Level 40.76
2nd Support Level 39.35

See More

52-Week High 136.90
Fibonacci 61.8% 99.98
Fibonacci 50% 88.57
Fibonacci 38.2% 77.17
Last Price 42.18
52-Week Low 40.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar